Schedule of Long-lived Assets by Geographic Area |
Our long-lived assets (which are comprised of our net property and equipment) by geographic area at December 31, 2021, 2020 and 2019, consisted of the following (in thousands): | | | | | | | | | | | | 2021 | | 2020 | | 2019 | United States | | $ | 275,311 | | $ | 277,643 | | $ | 273,816 | Ireland | | | 39,863 | | | 42,951 | | | 44,912 | Other foreign countries | | | 56,484 | | | 62,134 | | | 60,057 | Total | | $ | 371,658 | | $ | 382,728 | | $ | 378,785 |
|
Schedule of Segment Reporting Information, by Segment |
Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2021, 2020 and 2019, are as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2021 | | 2020 | | 2019 | Net Sales | | | | | | | | | Cardiovascular | $ | 1,043,227 | | $ | 934,202 | | $ | 960,981 | Endoscopy | | 31,524 | | | 29,673 | | | 33,871 | Total net sales | | 1,074,751 | | | 963,875 | | | 994,852 | | | | | | | | | | Operating Income (Loss) | | | | | | | | | Cardiovascular | | 53,415 | | | (7,042) | | | 25,780 | Endoscopy | | 7,501 | | | 5,480 | | | (10,346) | Total operating income (loss) | | 60,916 | | | (1,562) | | | 15,434 | | | | | | | | | | Total other expense - net | | (6,999) | | | (11,669) | | | (13,241) | Income tax expense (benefit) | | 5,463 | | | (3,388) | | | (3,258) | | | | | | | | | | Net income (loss) | $ | 48,454 | | $ | (9,843) | | $ | 5,451 |
Total depreciation and amortization by operating segment for the years ended December 31, 2021, 2020 and 2019, consisted of the following (in thousands): | | | | | | | | | | | | 2021 | | 2020 | | 2019 | Cardiovascular | | $ | 83,000 | | $ | 93,160 | | $ | 91,151 | Endoscopy | | | 1,066 | | | 910 | | | 949 | Total | | $ | 84,066 | | $ | 94,070 | | $ | 92,100 |
Total capital expenditures for property and equipment by operating segment for the years ended December 31, 2021, 2020 and 2019, consisted of the following (in thousands): | | | | | | | | | | | | 2021 | | 2020 | | 2019 | Cardiovascular | | $ | 27,557 | | $ | 45,803 | | $ | 77,631 | Endoscopy | | | 382 | | | 185 | | | 542 | Total | | $ | 27,939 | | $ | 45,988 | | $ | 78,173 |
|
Reconciliation of Assets from Segment to Consolidated |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | 2021 | | 2020 | | 2019 | Net Sales | | | | | | | | | Cardiovascular | $ | 1,043,227 | | $ | 934,202 | | $ | 960,981 | Endoscopy | | 31,524 | | | 29,673 | | | 33,871 | Total net sales | | 1,074,751 | | | 963,875 | | | 994,852 | | | | | | | | | | Operating Income (Loss) | | | | | | | | | Cardiovascular | | 53,415 | | | (7,042) | | | 25,780 | Endoscopy | | 7,501 | | | 5,480 | | | (10,346) | Total operating income (loss) | | 60,916 | | | (1,562) | | | 15,434 | | | | | | | | | | Total other expense - net | | (6,999) | | | (11,669) | | | (13,241) | Income tax expense (benefit) | | 5,463 | | | (3,388) | | | (3,258) | | | | | | | | | | Net income (loss) | $ | 48,454 | | $ | (9,843) | | $ | 5,451 |
|